>
Clinigen logo

CLIN - Clinigen Share Price

850p 0.5  0.1%

Last Trade - 16/04/21

Sector
Healthcare
Size
Mid Cap
Market Cap £1.13bn
Enterprise Value £1.48bn
Revenue £518.7m
Position in Universe 412th / 1819
Bullish
Bearish
Unlock CLIN Revenue
Momentum
Relative Strength (%)
1m +8.29%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -9.57%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
184.4 339.9 302.3 381.2 456.9 504.3 538.9 651.8 +22.3%
+36.9 +1.5 +1.9 +17.7 +12.1 +0.2 +55.3 +20.6
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 31 December 2020, ClinigenGroup PLC revenues increased 6% to £258.1M. Net incomedecreased 4% to £18M. Revenues reflect Clinical Trialservices segment increase of 25% to £89.9M, CommercialMedicines segment increase of 5% to £79.6M. Net income wasoffset by Amortization of Computer Software in SGA increasefrom £1.1M to £3.7M (expense), Other Non Rec I/E-NonBusiness Activ decrease of 48% to £1.3M (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for CLIN
Graphical History

Revenue

CLIN Revenue Unlock CLIN Revenue

Net Income

CLIN Net Income Unlock CLIN Revenue

Normalised EPS

CLIN Normalised EPS Unlock CLIN Revenue

PE Ratio Range

CLIN PE Ratio Range Unlock CLIN Revenue

Dividend Yield Range

CLIN Dividend Yield Range Unlock CLIN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
CLIN EPS Forecasts Unlock CLIN Revenue
Profile Summary

Clinigen Group plc is a United Kingdom-based pharmaceutical and services company. The Company's principal activities include management, sale and distribution of pharmaceutical products, which have associated expiry dates. The Company operates through five segments: Clinigen Clinical Trial Services (CTS), which sources commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs and rescue therapies; Idis Managed Access (MA), which is engaged in the consultancy, development, management and implementation of managed access programs for biotechnology and pharmaceutical companies; Idis Global Access (GA), which offers ethical access to post approval and short-supply medicines; Clinigen Specialty Pharmaceuticals (SP), which manufactures and distributes its own and in-licensed specialist, hospital-only medicines around the world, and Link Healthcare, which distributes pharmaceutical products in South Africa, and the Asia and Pacific region.

Directors
Last Annual June 30th, 2020
Last Interim December 31st, 2020
Incorporated December 12, 2008
Public Since September 25, 2012
No. of Shareholders: n/a
No. of Employees: 25
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Aim All Share , FTSE Aim 100 , FTSE Intl-aim UK 50 ,
Exchange London Stock Exchange (AIM)
Shares in Issue 133,029,000
Free Float (0.0%)
Eligible for
ISAs
SIPPs
CLIN Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for CLIN
Upcoming Events for CLIN
Monday 13th September, 2021 Estimate
Full Year 2021 Clinigen Group PLC Earnings Release
Frequently Asked Questions for Clinigen
What is the Clinigen share price?

As of 16/04/21, shares in Clinigen are trading at 850p, giving the company a market capitalisation of £1.13bn. This share price information is delayed by 15 minutes.

How has the Clinigen share price performed this year?

Shares in Clinigen are currently trading at 850p and the price has moved by 37.65% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Clinigen price has moved by 10.09% over the past year.

What are the analyst and broker recommendations for Clinigen?

Of the analysts with advisory recommendations for Clinigen, there are there are currently 4 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Clinigen is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Clinigen next release its financial results?

Clinigen is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Clinigen dividend yield?

The Clinigen dividend yield is 0.9% based on the trailing twelve month period.

Does Clinigen pay a dividend?

Last year, Clinigen paid a total dividend of 0.08, and it currently has a trailing dividend yield of 0.9%. Looking ahead, Clinigen has not announced an ex-dividend date yet.

When does Clinigen next pay dividends?

Clinigen has yet to annouce their ex-dividend date. The historic dividend yield on Clinigen shares is currently 0.9%.

How do I buy Clinigen shares?

To buy shares in Clinigen you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Clinigen?

Shares in Clinigen are currently trading at 850p, giving the company a market capitalisation of £1.13bn.

Where are Clinigen shares listed? Where are Clinigen shares listed?

Here are the trading details for Clinigen:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: CLIN
What kind of share is Clinigen?

Based on an overall assessment of its quality, value and momentum, Clinigen is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Clinigen share price forecast 2021?

Shares in Clinigen are currently priced at 850p. At that level they are trading at 24.29% discount to the analyst consensus target price of 1,122.71.

Analysts covering Clinigen currently have a consensus Earnings Per Share (EPS) forecast of 0.62732 for the next financial year.

How can I tell whether the Clinigen share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Clinigen. Over the past six months, the relative strength of its shares against the market has been 11.76%. At the current price of 850p, shares in Clinigen are trading at 21.63% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Clinigen PE Ratio?

The Clinigen PE ratio based on its reported earnings over the past 12 months is 22.43. The shares are currently trading at 850p.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Clinigen?

Clinigen's management team is headed by:

Shaun Chilton - CEO
Ian Nicholson - NID
Peter Allen - NEC
Anne Hyland - NID
Amanda Miller - GCN
Alan Boyd - NED
Nick Keher - CFO
Sam Herbert - COO
Who are the major shareholders of Clinigen?

Here are the top five shareholders of Clinigen based on the size of their shareholding:

Rathbone Investment Management Ltd. Investment Advisor/Hedge Fund
Percentage owned: 6.05% (8.05m shares)
Janus Henderson Investors Investment Advisor/Hedge Fund
Percentage owned: 5.56% (7.40m shares)
Octopus Investments Limited Investment Advisor
Percentage owned: 5.08% (6.75m shares)
Jupiter Asset Management Ltd. Investment Advisor/Hedge Fund
Percentage owned: 5.03% (6.70m shares)
AXA Investment Managers UK Ltd. Investment Advisor/Hedge Fund
Percentage owned: 4.56% (6.06m shares)
Similar to CLIN
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.